Abstract 221P
Background
Breast cancer recurrences (BCR) are among the leading causes of deaths related to this malignancy’s progression. Many experts have tried to create several clinical calculators, also known as nomograms, to prognose treatment outcomes and recurrent disease. To these date, no analyses have reported diffrerances in the characteristics between early and late BCR and the relation to their rate according to the level of adherence(LA) to medical standards (MS).
Methods
In this prospective comparison studу, we investigated data from 132 patients with early BCR and 131 patients with late BCR (> 5 years after primary surgery). Early and late BCR were diagnosed and treated between 2012 and 2020, at two centers. Primary breast cancers (BC) were treated in many different hospitals. The LA to MS was assessed by 4a, 10a, 10b, 10c, 11a, 11c, 12, 13a, and 13b quality indicators adopted by European Society of Breast Cancer Specialists.
Results
The time interval between the primary tumor (PT) and the early BCR was from 1 month to 5 years, and for the late recurrence - from 6 to 36 years. 25,8% of early BCR (12,9% of all BCR) were diagnosed less than 1 year after primary surgery. There was a significant difference between patients with early and late recurrence who had family history of BC (the early BCR - 39,4%; the late BCR – 49,6%). The majority of PTs were in T1 stage: 75,76% of early BCR and 61,8% of late BCR. Regional lymph nodes could not be assessed (Nx) in 13,6% of patients with PTs and early BCR, which leads to a significant decrease in LA to MS in these patients. 67,3% of all relapsing patients had high ER+ titers (≥50 %). We reported HER2-negative status in 83,3% of patients with the early BCR and in 87,02% of late relapsing patients. The LA to MS is faintly 76,3% in PTs. The results include significant differences in the LA to MS according to early and late BCR, the patients' age and clinical treatment, and can be used as prognostic factors.
Conclusions
Despite the many efforts that have been made in the quality of BC care, it would be greatly improved if we reduce recurrences. Noting the differences in characteristics between early and late local BCR and the relation to their rate according to the LA to MS, can aid in the development of treatment strategies and follow-up in these at-risk patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.